Micregen

Investment
Micregen Investors
Transforming Infant Care and Extending Healthy Lifespan
Micregen’s lead therapeutic candidate, MRG1061, is being advanced toward clinical trials with the aim of treating the strategically chosen orphan diseases necrotising enterocolitis (NEC) and bronchopulmonary dysplasia (BPD) in babies. These devastating neonatal conditions represent areas of urgent unmet medical need, and successful progress here will establish Micregen as a leader in cell-free regenerative medicine.Beyond this initial focus, Micregen’s long-term aspiration is to extend the benefits of its proprietary Secretomix® platform into wider indications, particularly degenerative diseases and therapies that promote healthy longevity. By tackling diseases of early life while building toward solutions for conditions associated with ageing, Micregen aims to improve outcomes across the full human lifespan.

As a privately held UK-registered company, Micregen is owned by founders, angel investors, and life science professionals, and is led by a Board with deep scientific and commercial expertise. Its mission aligns closely with the UK Government’s target to increase healthy life expectancy by five years by 2035.

The foundation of Micregen’s innovation lies in pioneering stem cell discoveries dating back to 1993, coupled with decades of research that challenged conventional scientific wisdom. Careful stewardship of resources, combined with strong academic, clinical, and industry collaborations, has enabled the company to advance Secretomix® to a stage ready for first-in-human trials with MRG1061.

Micregen is now poised to demonstrate both its clinical impact in orphan diseases and its commercial potential in the rapidly growing longevity industry, where the ability to extend healthy years of life offers substantial returns alongside transformative benefits for patients worldwide

Your Investment Opportunity

We welcome interest from potential investors who want to know more about our cutting-edge innovation.

Get in touch with us
Contact Us
Making an Impact Investment

A recent survey conducted by the Department for International Development highlighted that more than 68% of savers in the UK wanted their investments to be good for people and the planet. This sentiment is well aligned with Micregen’s ambition.

Investing for positive impact goes beyond avoiding harm and mitigating risks and is at the centre of a broader movement towards more responsible investing.

For Investors, Micregen meets the following criteria:
Early deal access to a private company targeting an emerging area of life science
Disruptive first-in-class opportunity
Ambitious strategy to address areas of high unmet need
Significant global market potential
Proprietary platform technology with potentially wide utility across diseases
Highly scalable opportunity
EIS Relief for qualifying investors
Experienced and passionate team capitalising on the founders’ lifetime work
Extensive Key Opinion Leaders (KOL) advisor network & 3rd party validation
An ethical business aiming to generate a meaningful difference to society.

We look forward to contact from anyone who shares our values, ambition, and passion for healthcare of the future.

Investment Form